Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 12

Change from baseline in eGFR over the 24-week follow-up period in the CKD stage 3a subgroup.

Time	Treatment group	Control group	Effect	F value	value
Pretreatment (ml/min/1.73 m^2)	52.18 ± 4.14	51.85 ± 4.44	Time effect	2.08	0.0664
Week 4 (ml/min/1.73 m^2)	58.06 ± 9.04	53.18 ± 8.45	Difference between groups	33.59	<0.0001
Week 8 (ml/min/1.73 m^2)	60.45 ± 10.28	52.04 ± 10.41
Week 12 (ml/min/1.73 m^2)	60.43 ± 10.64	53.56 ± 11.24
Week 16 (ml/min/1.73 m^2)	61.54 ± 11.18	52.17 ± 10.48
Week 20 (ml/min/1.73 m^2)	61.60 ± 10.82	52.61 ± 10.65
Week 24 (ml/min/1.73 m^2)	61.77 ± 10.78	52.63 ± 11.63